To improve prognosis in acute coronary syndrome, new clinical applications in terms of
diagnosis, risk stratification, and treatment strategies are still under investigation. Ischemia …

Background: The diagnosis of acute coronary syndrome remains challenging, as cardiac
troponins and creatine kinase-MB do not detect myocardial ischemia. Ischemia modified …

Background: Ischemia-modified albumin has been proposed as a useful rule-out marker for
the diagnosis of acute coronary syndrome in the emergency department. Objective: To …

Background Ischemia-modified albumin (IMA) has been shown to be a rapidly rising and
sensitive biochemical marker especially for the diagnosis of myocardial ischemia. The aim of …

Objectives Ischemia-modified albumin (IMA), a new serum biomarker of myocardial
ischemia, has been introduced in the diagnosis of acute coronary syndrome. However, few …

Ischemia-modified albumin (IMA) is a laboratory biomarker of cardiac ischemia. Our study
aims to determine whether IMA can estimate or represent to any degree the extent of …

BACKGROUND: Existing cardiac markers are not sensitive for reversible myocardial
ischemia. Ischemia modified albumin (IMA) has recently been shown to be an early and …

Ischemia modified albumin (IMA), as measured using the albumin cobalt binding test, is
currently the most promising biomarker for early detection of ischemia before the onset of …

Diagnosis of cardiac ischemia in patients coming to emergency departments (ED) with
symptoms of acute chest pain is often difficult. Many markers are sensitive and specific for …

ABSTRACT Aims and Objectives: To find out if ischemia modified albumin can be a novel
marker in ischemic heart disease. Materials and methods: Retrospective chart-review of …